Furthermore, profiling of apelinergic biomarkers (apelin and ELA levels) may aid in prognostication of cardiovascular diseases—e.g., by identifying high-risk patients in need of more intensive therapy. This evidence concerns the gene APLN and cardiovascular disorder.